Head of U.S. Epilepsy Marketing
Jason Joseph joined UCB in 2000 and entered the epilepsy space when he began working on Keppra® (levetiracetam), where he didn’t just lead the brand to new levels of success, but changed the way people think of epilepsy. Jason was at the forefront of combating the stigma attached to epilepsy by successfully launching multiple indications and formulations to HCPs and building patient programs that run the gamut of what was then possible: Live patient meetings, online communities and informational resources, over-the-phone mentor programs, and video campaigns. In the end, Keppra surpassed Wall Street’s wildest expectations by becoming a blockbuster AED due to the work Jason and UCB undertook along with launching one of the first Patient Advocate platforms in the industry.
Jason was also there when UCB launched Vimpat® (lacosamide), thereby really continuing to solidify UCB as “The Epilepsy Company.” In 2012, he went on to manage the pre-commercialization efforts in movement disorders to successfully launch Neupro® (rotigotine), an equally impressive launch that affirmed UCB’s firm position in the neurology space. In 2014, Jason moved back on to the Vimpat team to lead the launch of its monotherapy indication. From the beginning of his time in leadership, Jason placed his bets on patients—realizing that success would hinge on the ability to connect the brand to consumers. As a result, the brand grew to one of the top leaders, and is on its way to becoming the next blockbuster AED.
Through his roles at UCB, Jason has made it his mission to drive innovative ways to create value for patients and the epilepsy community, thereby supporting UCB’s effort to become the patient-preferred biopharmaceutical company. Jason also donates his personal time as a member of both the Epilepsy Foundation of Georgia and the National Epilepsy Foundation of America.
For the past two and a half years, Jason has led UCB’s U.S. epilepsy marketing team and has been responsible for the strategic direction of the company’s current epilepsy portfolio, including Vimpat and Keppra, as well as the commercialization of Briviact® (brivaracetam), the latest compound continuing the mission to support the epilepsy community.